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Background: In general, safety data following exposure to drugs in the first trimester of pregnancy are scarce. More
specifically, data on the safety of artemisinin-based combination therapy (ACT) in pregnancy still remain limited. Therefore,
pregnant women from Choma, Zambia, who were exposed to artemether-lumefantrine (AL) for the treatment of
uncomplicated malaria were followed up and evaluated in a prospective cohort study. This report assessed the
longitudinal safety outcomes of the pregnant women inadvertently exposed during the first trimester.
Methods: Participants were classified based on the drug used to treat their most recent malaria episode:
artemether-lumefantrine (AL) versus sulphadoxine-pyrimethamine (SP) and/or quinine. All enrolled women were
followed up until six weeks post-delivery and the live births for 12 months.
Results: There were 294 first trimester exposures in the observational cohort (pregnant women: AL = 150, AL and
SP = 9 and SP and/or quinine = 135). Similar rates of perinatal mortality (stillbirths and neonatal deaths) were
observed for each treatment arm (AL 4.4%, SP and/or quinine 3.9%). At delivery (newborns: AL = 135, AL and SP
= 7 and SP and/or quinine = 129), the gestational age (measured using the Dubowitz total scores), length and
head circumference of the newborns were similar between the two arms. Low birth weights were reported in
10.2% (95% CI 6.0, 16.6) and 6.7% (95% CI 3.4, 12.6) of newborns in the AL and SP and/or quinine arms,
respectively. Overall development (including neurodevelopmental parameters) was similar between the two arms,
both at 14 weeks and 12 months of age.
Conclusion: Exposure to AL and SP in the first trimester was not associated with particular safety risks such as
perinatal mortality, preterm deliveries or low birth weights. Such outcomes as well as infant neurodevelopmental
parameters up to 12 months were similar between the two arms. These findings add to the body of data
suggesting that randomized clinical trials could now be the way forward to assess safety and efficacy of ACT in
the first trimester of pregnancy.Background
Women of childbearing age are at increased risk of mal-
aria during pregnancy and the consequences of infection
can be significant for them and for the fetus [1-3]. Al-
though all malaria infections during pregnancy can affect
maternal and foetal health, Plasmodium falciparum in-
fection is associated with the most severe effects and has
been linked to increased maternal, foetal and neonatal* Correspondence: cmanyando@yahoo.com
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transmission, asymptomatic malaria in pregnancy is
associated with severe maternal anaemia, placental
parasitaemia and low birth weight – a risk factor for
death [6,7]. In areas of unstable transmission, preg-
nant women are at increased risk of severe malaria
[3,7]. Therefore, it is important to ensure that effective
prevention measures and treatments reach pregnant
women in malaria endemic areas [6,8,9].
The World Health Organization (WHO) recommends the
use of preventive measures to limit the occurrence of malaria
in pregnancy, including the use of insecticide-treated netstral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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treatment (IPTp) in areas of stable malaria transmission. It
also recommends that all cases of malaria during pregnancy
should be treated promptly with an effective anti-malarial
drug [10,11].
In the general non-pregnant population, artemisinin-based
combination therapy (ACT) is the currently recommended
first-line treatment for uncomplicated P. falciparum malaria
and is known to be effective and well tolerated [12].
Risk-benefit data from 1,500 documented pregnancies
exposed to artemisinin during the second or third trimes-
ter enabled the WHO to recommend the use of ACT as a
first-line therapy to treat uncomplicated P. falciparum
malaria during the second and third trimesters of preg-
nancy [13]. The recommended ACT for treatment includes
artemether-lumefantrine (AL), artesunate-amodiaquine
(AS-AQ), artesunate-mefloquine (AS-MQ) and artesunate-
sulphadoxine-pyrimethamine (AS+SP), but excludes
dihydroartemisinin-piperaquine (DHA-PPQ) because
of lack of sufficient data for use of this combination
in the second and third trimesters [13].
ACT is not recommended during the first trimester
due to limited clinical safety data [13] and evidence of
embryo lethality and some developmental abnormalities
in animal studies [14,15]. WHO recommends a 7-day
course of quinine plus clindamycin (or quinine
monotherapy if clindamycin is not available) as the
first-line malaria treatment in the first trimester, al-
though there are concerns regarding poor tolerability
(and compliance) related to quinine. Artesunate plus
clindamycin is the recommended second-line treat-
ment [13]. Other artemisinin-based combinations are
indicated only if the recommended treatments are not
available or have failed.
The necessary exclusion of pregnant women from clin-
ical trials, including the original studies of artemisinins
and ACT, and dependence upon observational studies
explain the scarcity of data in this vulnerable population
[16]. Consequently, monitoring the safety of ACT in
first-trimester pregnancy still remains an important area
of malaria research. An understanding of the risks and
benefits of ACT during early pregnancy is needed to
guide policymakers and healthcare workers, and ensure
that pregnant women receive both effective and safe
treatments for malaria [16]. A population-based study
carried out in Thailand with over 17,000 participants in-
cluding 945 women who had malaria in the first trimes-
ter reported that first trimester exposure to artesunate
showed no significant difference in birth outcomes as
compared to quinine or chloroquine [17]. Treatment re-
lated adverse effects were not seen, although the number
of women treated with artesunate was small [17].
In Zambia, AL is the first-line drug for treatment of
malaria in the general population. As per WHOguidelines, it is contraindicated in the first trimester of
pregnancy. However, this anti-malarial is sometimes
used in practice during the first trimester, because
women often do not disclose their pregnancy in the early
stages for cultural reasons. In a previously reported ob-
servational study conducted in Zambia from 2004 to
2008 [18], some women were inadvertently exposed to
AL in the first trimester of pregnancy. The safety data
from these exposures to AL or SP and/or quinine in the
first trimester of pregnancy form the basis of this report.
Methods
Study population
The first trimester exposed pregnant women were part
of the observational cohort study that was carried out in
Zambia at four antenatal clinics in the districts of
Choma, Ndola and Lusaka from October 2004 to July
2008 [18]. These women were eligible for inclusion if
they had received AL or SP and/or quinine for the treat-
ment of uncomplicated malaria. Diagnosis was clinically
or parasitologically confirmed. At the time, SP was the
standard anti-malarial treatment during pregnancy, and
was also used for IPTp. Pregnant women were assigned
to treatment arms according to the treatment received
for the “index episode”, defined as the most recently
treated malaria episode prior to study entry.
Study procedures
Data from women who had inadvertent first trimester
exposure to AL were analysed descriptively to compare
outcomes between first trimester and second and third
trimester exposures for the following (first trimester)
subgroups: exposure to AL alone; exposure to AL plus
other anti-malarials; exposure to anti-malarial(s) other
than AL; no anti-malarial drug exposure; and unknown
anti-malarial drug exposure (due to missing or incom-
plete last menstrual period [LMP] date).
The primary endpoint for the prospective cohort was
the incidence of perinatal mortality (stillbirth or neonatal
death within seven days of birth). Secondary endpoints
were gestational age at delivery and birth weight ad-
justed for gestational age [19]. A newborn was consid-
ered to have low birth weight if the observed birth
weight was lower than the corresponding 5th percentile
of the Zimbabwean birth weight according to gestational
age, in keeping with international standards. Exploratory
measures that were assessed included frequency of spon-
taneous abortion, preterm delivery, neonatal mortality,
maternal mortality, major and minor birth defects, and
infant development including neurological development.
Women attending antenatal clinics were enrolled if
they reported receiving treatment with either AL (20 mg
artemether plus 120 mg lumefantrine) or SP (1500 mg
sulphadoxine plus 75 mg pyrimethamine) and/or
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was verified by documentation from outpatient clinic
files, which also detailed any diagnostic procedures per-
formed and concomitant medications given. As per
government policy, women received SP, at the doses de-
scribed above, during the second or third trimester as
IPTp. Treatment with other drugs, including anti-malarials,
prior to or after the index episode was recorded [18].
First trimester pregnancies were defined as pregnan-
cies with a gestational age of less than 14 weeks. Women
visited the antenatal clinics for assessment of safety pa-
rameters at baseline/enrolment, 4 weeks post-enrolment,
4 weeks pre-delivery, at delivery, and at 6 weeks post-
delivery. Infants were followed up at 6 weeks, 14 weeks
and 12 months after birth.
At delivery, the newborn’s vital signs and APGAR
score at one minute, five minutes and 10 minutes after
birth were recorded. Birth weight was measured in
grams using a digital scale with a precision of two deci-
mal points. At the antenatal care clinics, study partici-
pants were encouraged to deliver at the health facility by
the study midwives. For deliveries outside of the health
facility, birth weight was measured at a health facility
within 24 hours after birth if such a visit occurred. Qual-
ity control measures included monthly calibration of the
baby scales using standard pre-measured commercially
purchased weights. The gestational age was estimated
from the date of the LMP and was confirmed using the
Dubowitz neurological and external criteria for gesta-
tional age assessment at birth. The study midwives who
performed these assessments were trained by the study
paediatrician. Detection of major and minor birth de-
fects was performed by study nurse/midwives in accord-
ance with the data collection form (checklist) at birth
and at 6 weeks post-delivery in home delivery cases. The
study physicians re-assessed babies with congenital mal-
formations to confirm findings. They also periodically
and randomly verified measurements of head circumfer-
ence and length. In addition, the study paediatrician vis-
ited the health facilities periodically to review gestational
age assessments and verified congenital malformations.
Safety assessments included monitoring and recording
of all adverse events (AEs) and serious adverse events
(SAEs) up to six weeks post-delivery. Pregnancy-specific
assessments included rates of perinatal mortality defined
as stillbirth (>28 weeks gestation) and early neonatal
death (within seven days of birth); neonatal mortality
(≤28 days of birth); maternal mortality (up to six weeks
post-delivery); spontaneous abortion (≤28 weeks gesta-
tion); stillbirth; preterm delivery (≤37 completed weeks);
incidence of low birth weight; gestational age at delivery
(estimated from LMP, or by a Dubowitz score [20,21] if
the LMP was unknown); and incidence of major and
minor birth defects. Concomitant infections were recorded.Both major and minor birth malformations were docu-
mented using a checklist [18].
Neurodevelopmental assessment was performed by the
investigators at 14 weeks and 12 months after birth, ei-
ther through a general assessment (e.g. smiling, lifting
head, sitting unsupported, standing without assistance,
and crawling) or the Shoklo neurodevelopment assess-
ment [22], or both.
This study was designed, implemented, and reported
in accordance with ICH Good Clinical Practice, applic-
able local regulations, and the Declaration of Helsinki.
The study protocol was first approved by the Institu-
tional Review Boards at Tropical Diseases Research
Centre, Zambia (TDRC) and WHO/TDR in Geneva be-
fore approval by the local Ethics Review Committee of
the TDRC, and WHO Ethics Review Committee, Geneva.
All participants, or their parent/guardian (if the subject
was a minor), gave written or finger-marked informed
consent before study entry. An independent Study Advis-
ory Committee reviewed unblinded data for the whole co-
hort, including the first trimester exposures during and at
the end of the study.
Results
This report concentrates on first trimester exposures as
analyses of the full cohort were previously published
[18]; as a result there is some overlap with published re-
sults. Women with first trimester exposures had similar
baseline characteristics to the overall cohort. Over 95%
attained primary education and over 52% attained sec-
ondary education. Alcohol intake was similar between
the treatment arms, not exceeding 3%. None of the
women were smokers. Age ranges and weight profiles
across the treatment groups were similar (Table 1).
The study population was selected based on treatment
received for the most recent (index) episode of uncom-
plicated malaria prior to enrolment. The index malaria
episode was predominantly diagnosed based on symp-
toms. In total, 294 women out of the cohort of 1,001
(29.4%) received treatment in the first trimester of preg-
nancy. Of these, 156 women (150/495 (30.3%)) from the
AL group, plus six from the SP group) received AL
treatment during the first trimester, while 138 women
(135/506 (26.7%)) from the SP and/or quinine group,
plus three from the AL group) received SP treatment
during the first trimester (Figure 1). Women with first
trimester anti-malarial treatment also received concomi-
tant medications such as haematinics (oral iron prepara-
tions and folic acid).
Despite counselling of all enrolled women on human
immunodeficiency virus (HIV) testing, only 30% in the
AL arm and 38% in the SP arm agreed to be tested; 7.2%
of those with a test result were HIV positive (AL 7.3%,
SP and/or quinine 7.1%). Respiratory tract infections
Figure 1 First trimester exposures (within cohort).
Table 1 Age, body weight at enrolment and treatment courses during first trimester including IPTp with SP
Exposure group
AL, N=150 AL* and SP†, N=9 SP† and/or quinine, N=135 No anti-malarial, N=667 Unknown anti-malarial, N=40
Age group, n (%)
<20 years 20 (13.3) 1 (11.1) 14 (10.4) 118 (17.7) 7 (17.5)
20-24 years 56 (37.3) 5 (55.6) 41 (30.4) 204 (30.6) 12 (30.0)
25-29 years 35 (23.3) 2 (22.2) 44 (32.6) 199 (29.8) 12 (30.0)
30-39 years 36 (24.0) 1 (11.1) 35 (25.9) 139 (20.8) 9 (22.5)
>40 years 3 (2.0) 0 (0) 1 (0.7) 7 (1.1) 0 (0)
Body weight (kg)
Mean (± SD) 61.2 (±9.8) 60.3 (±10.1) 60.8 (±10.0) 60.3 (±10.1) 60.8 (±10.0)
Median 60.0 59.0 60.0 59.0 59.7
AL = artemether-lumefantrine; SP = sulphadoxine-pyrimethamine.
*AL treatment in first trimester; †SP treatment in first trimester.
Exposure groups represent the treatment given to the pregnant woman for the malaria episode that had occurred most recently prior to enrolment (= index episode).
Manyando et al. Malaria Journal  (2015) 14:77 Page 4 of 9
Table 2 Delivery outcomes by anti-malarial drug exposure during first trimester
Exposure group










Normal 129 (86.0) 6 (66.7) 125 (92.6) 623 (91.1) 39 (92.9)
Caesarian section 4 (2.7) 0 (0) 4 (3.0) 21 (3.1) 1 (2.4)
Other (instrumental deliveries) 2 (1.3) 1 (11.1) 0 (0) 0 (0) 0 (0)
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SP and/or quinine arms, respectively. Other infec-
tions (e.g. urinary tract infections, syphilis) were re-
corded less frequently. Non-infection-related medical
conditions were recorded in ≤2% of women in either
arm.
As reported previously [18], patients exposed only to
AL during the first trimester had similar rates of pre-
term and full term deliveries to patients who did not
receive anti-malarials during the first trimester; 86% of
these women had normal deliveries (Table 2). A small pro-
portion had caesarean sections (AL 2.7%, SP and/or quinine
3.0%).
Birth weights and birth weights adjusted for gesta-
tional age by exposure group were generally similar (low
birth weights: AL 10.2% (95% CI 6.0, 16.6), SP and/or
quinine 6.7% (95% CI 3.4, 12.6) and no anti-malarials
8.7% (95% CI 6.7, 11.2)). There were no major differ-
ences between newborns of women who were exposed
to AL only, anti-malarials other than AL (SP and/or quin-
ine), or no anti-malarials during first trimester (Table 3).
The assessments performed at birth such as gesta-
tional age calculated from total Dubowitz scores, new-
born length and head circumference showed no major
differences across the exposure groups (Table 4). These
are not depicted according to international standards for
reporting by gestational age and sex due to lack of
Zambian references for newborn measurements of
weight, length and head circumference [23].Table 3 Newborn birth weight and birth weight adjusted for ge









N 128 7 120
Mean 3043 3010 3065
Standard deviation 560 690 466
Birth weight (g) adjusted for gestational age
Low 13 (10.2) 1 (14.3) 8 (6.7)
Normal 115 (89.8) 6 (85.7) 112 (93.3
Missing 5 0 6
Birth weights from singleton live births only, measured within 24 hours of delivery.There were generally no major differences across the
exposure groups in adverse birth outcomes among the
women with complications. There were more premature
births among the babies born to women exposed to SP
and/or quinine (23%; 95% CI 16.7, 30.7) than those ex-
posed to AL (16.7%; 95% CI 11.6, 23.5), but the differ-
ence was not statistically significant. There were no
other differences between the arms.
Table 5 disaggregates perinatal and neonatal deaths by
time. Perinatal mortality outcomes were similar for the AL
group (4.4%; 95% CI 2.1, 9.4), the SP and/or quinine group
(3.9%; 95% CI 1.7, 8.8) and those who had no anti-malarial
exposure in first trimester (4.8%; 95% CI 3.4, 6.8). Early
neonatal deaths (i.e. within 28 days) were also similar for
the AL exposure group (3.8%; 95% CI 1.6, 8.5) as com-
pared with those who had no anti-malarial exposure in the
first trimester (3.0%; 95% CI 1.9, 4.7).
The number of malformations in 130 babies born to
mothers who received only AL in the first trimester was
9 (6.9%), and this frequency was not different from that
of patients exposed to other anti-malarials (8/121, 6.6%).
In all but one case of exposure only to AL, the malfor-
mations were umbilical hernias. For all infants with um-
bilical hernia, the hernia was not detected at birth, but
at week 6 (6 cases) or week 14 (2 cases) visits post-
delivery.
Neurodevelopmental assessment of infants from the
Choma site using the Shoklo development test is sum-
marized according to anti-malarial exposure in the firststational age by exposure group, according to anti-malarial







, n (%) [19]
52 (8.7) 0 (0)
) 545 (91.3) 34 (100.0)
30 6
Table 4 Newborn gestational age, length and head circumference, according to anti-malarial drug exposure during
first trimester
Exposure group
AL only, N=133 AL and SP, N=7 SP and/or quinine, N=126 No anti-malarial, N=627 Unknown anti-malarial, N=40
Gestational age (weeks)
Minimum 28.8 28.8 28.8 28.8 17.0
25th Quartile 36.2 36.2 37.0 36.5 36.2
Median 37.7 37.7 37.7 37.8 38.1
75th Quartile 38.9 38.9 39.6 38.9 38.9
Maximum 41.8 41.8 42.0 41.8 41.8
Length (cm)
Minimum 27.0 30.0 34.0 30.0 31.0
25th Quartile 48.0 48.0 47.0 48.0 47.0
Median 49.0 49.4 49.0 49.0 49.0
75th Quartile 50.0 50.0 50.0 50.0 50.0
Maximum 60.0 60.0 59.0 60.0 59.0
Head circumference (cm)
Minimum 24.0 24.0 24.0 24.0 24.5
25th Quartile 34.0 34.0 34.0 34.0 34.0
Median 36.0 35.4 35.0 36.0 35.0
75th Quartile 37.0 36.0 36.0 37.0 36.0
Maximum 41.0 43.0 43.0 41.0 44.0
Table 5 Perinatal and neonatal mortality by anti-malarial drug exposure during first trimester
Exposure group
Outcome of deliveries (N*) AL only, N=135,
n (%), (95% CI)
AL and SP, N=7,











Perinatal mortality, n (%) 6 (4.4) 1 (14.3) 5 (3.9) 31 (4.8) 1 (2.5)
(2.1, 9.4) (2.6. 51.3) (1.7, 8.8) (3.4, 6.8) (0.4, 12.9)
Stillbirth (>28 weeks gestation), n (%) 2 (1.5) 0 (0) 3 (2.3) 17 (2.6) 0 (0)
(0.4, 5.2) (0.0, 39.0) (0.8, 6.6) (1.7, 4.2) (0.0, 9.0)
Death ≤7 days after birth, n (%) 4 (3.0) 1 (14.3) 2 (1.6) 14 (2.2) 1 (2.5)
(1.2, 7.4) (2.6, 51.3) (0.4, 5.5) (1.3, 3.6) (0.4, 12.9)
Exposure group
Outcome of neonates (N†) AL only, N=133,
n (%), (95% CI)
AL and SP, N=7,











Neonatal mortality within 28 days of birth, n (%) 5 (3.8) 1 (14.3) 2 (1.6) 19 (3.0) 1 (2.5)
(1.6, 8.5) (2.6, 51.3) (0.4, 5.6) (1.9, 4.7) (0.4, 12.9)
Infant mortality >28 days to 1 year afer birth‡ n (%) 8 (6.3) 0 (0.0) 1 (0.8) 21 (3.5) 0 (0.0)
(3.2, 11.9) (0.0, 39.0) (0.1, 4.4) (2.3, 5.2) (0.0, 9.0)
Total infant mortality within 1 year after birth, n (%) 13 (9.8) 1 (14.3) 3 (2.4) 40 (6.4) 1 (2.5)
(5.8, 16.0) (2.6, 51.3) (0.8, 6.8) (4.7, 8.6) (0.4, 12.9)
Perinatal mortality: stillbirth or early neonatal death within 7 days after birth; CI = confidence interval.
*All deliveries; †Total live births; ‡Denominators: AL only N=128; AL and SP N=6; SP and/or quinine N=124; No anti-malarial N=608; and Unknown anti-malarial N=39.
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14 weeks and 12 months after birth. The results of the
assessment appeared to be similar across all exposure
groups. At 14 weeks, 99% of infants of mothers who
received only AL during the first trimester had assess-
ments rated ‘good’ or ‘excellent’, as did 100% at 12 months.
There was no difference in scores for coordination, tone,
behaviour and overall milestones between the treatment
arms at 14 weeks and 12 months after birth. Results were
similar for infants of patients who received other anti-
malarials, or no anti-malarials, during the first trimester.Discussion
Although not recommended for use in the first trimester
of pregnancy, a substantial proportion of patients were
exposed to AL during this period. As it is a culturalTable 6 Neurodevelopmental assessment according to anti-m
Exposure group









Motor milestones 9.0 12.0 7.
(6.0-18.0) (12.0-13.0) (5
Coordination 5.0 10.0 5.
(4.0-20.0) (5.0-11.0) (4
Tone 18.0 18.0 18
(15.0-23.0) (17.0-19.0) (1




N=81, Mean (SD) N=3, Mean (SD) N
Height (cm) 59.9 (4.11) 59.6 (4.13) 59









Motor milestones 35.0 35.0 34
(25.0-37.0) (31.0-37.0) (2
Coordination 32.0 26.0 32
(19.0-34.0) (26.0-32.0) (5
Tone 20.0 18.0 19
(16.0-20.0) (17.0-20.0) (1




N=75, Mean (SD) N=3, Mean (SD) N
Height (cm) 70.5 (6.46) 69.0 (6.32) 68
Weight (kg) 9.5 (1.08) 9.4 (1.08) 9.
Neurodevelopmental assessment done in only 60% of all study participants.norm in Zambia not to disclose a pregnancy before it is
visible, it is probable that some women intentionally did
not disclose their pregnancies to their healthcare pro-
viders. Alternatively, some women may have been preg-
nant and were prescribed AL before they were aware of
their status as it is not routine practice to perform a
pregnancy test before administration of medications to
women of childbearing ages at outpatient clinics. As a
consequence of these unexpectedly high exposure rates
within the first few months after initiation of the obser-
vational cohort, the Central Board of Health (CBoH)
was persuaded to re-issue guidelines and distribute them
to all health institutions in the country emphasizing the
contraindication of AL in the first trimester.
Nevertheless, first trimester exposure to AL was not asso-
ciated with a greater risk of perinatal or neonatal death or
stillbirths even among women with complications atalarial drug exposure during first trimester
















=48, Mean (SD) N=367, Mean (SD) N=22, Mean (SD)
.2 (4.17) 59.6 (4.15) 59.8 (4.12)















=49, Mean (SD) N=365, Mean (SD) N=20, Mean (SD)
.9 (6.22) 70.0 (6.43) 69.0 (6.35)
4 (1.09) 9.3 (1.09) 9.4 (1.08)
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exposure group with spontaneous abortions, albeit
with additional first trimester risk factors (including
malaria or another febrile illness) associated with mis-
carriage [17]. Unfortunately, women who had febrile
illnesses presumed to be malaria had no parasito-
logical confirmation of malaria.
Though drug safety concerns still restrict the recom-
mended treatment for P. falciparum malaria in the first
trimester to a seven-day treatment with quinine, a
poorly tolerated, poorly adhered to, and therefore less
effective treatment testifies to the role malaria or other
febrile illnesses play in contributing to the adverse out-
comes of pregnancy. This does not mean that AL did
not cause or contribute to adverse pregnancy outcomes,
but rather that it is difficult to disentangle the effects of
malaria from those of its treatment, particularly in
women who may not yet know that they are pregnant.
Therefore, further studies to explore the safety and effi-
cacy of anti-malarials, which could be used in early preg-
nancy, are needed. Establishing the safety of artemisinins
in early pregnancy is an important area of research. In
the very large cohort from Thailand, exposure to arte-
misinin derivatives was not associated with miscarriage
after controlling for maternal and malaria characteris-
tics [17], and birth outcomes did not differ significantly
after first trimester treatment with artesunate com-
pared with other treatments, such as quinine and
chloroquine.
In the full cohort analysis [18], the profile of AEs re-
ported was unremarkable. Except for complications of
pregnancy, most of the commonly reported AEs were re-
lated to malaria or other infections [18]. The great major-
ity of the SAEs reported were related to complications of
pregnancy, mostly presenting as premature delivery. Other
SAEs were very infrequent and were mainly infections.
The study has some limitations. First, patients entered
the study after completing treatment for the index epi-
sode of malaria, and this made the tolerability of treat-
ment difficult to assess. Therefore, these safety data
reflect pregnancy-related outcomes in a malaria endemic
area of Zambia, including IPTp administration, rather
than AEs related to the treatment of an index malaria
episode. Furthermore, in 82% of the AL and 87.2% of
the SP patients, the index episode of malaria was uncon-
firmed either by microscopy or by rapid diagnostic test,
and it is therefore possible that some patients had febrile
illnesses other than malaria. Parasitological information
would have helped to better interpret the findings. Failure
to test for malaria was routine practice at the time of the
study. Today, following WHO treatment guidelines and
NMCP policy, ACT treatment of all patients, including
women of childbearing age, is only provided after para-
sitological testing.It was only possible to crudely estimate gestational age
using LMP as ultrasound was unavailable routinely.
Therefore, it is possible that some infants may have been
classified as premature when in reality they were not.
Nevertheless, there are recent data indicating that LMP
may be a more reliable method for measuring gesta-
tional age than previously thought [24].
Finally, due to lack of consenting for HIV testing by
the majority of women in the study, the rate of HIV in-
fection may have been considerably higher than 7%. Re-
ported rates of HIV infection in women attending
antenatal clinics in Zambia in 2002 ranged from 11% in
rural areas to 26% in urban areas [25].
Conclusion
Exposure to AL in the first trimester was not associ-
ated with higher risk of perinatal or neonatal mortal-
ity, premature delivery or low birth weight compared
with SP. Although limited, the available data add to
the evidence on the safety of AL and artemisinins in
general during first trimester pregnancy. Should evi-
dence continue to be reassuring, randomized clinical
trials might be considered to reliably determine the
safety and efficacy of ACT in the first trimester of
pregnancy.
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